KELSEY USSELMANN: Open Payments
NPI 1417510082 · WOODLAND HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$811 in 32 payments from 10 companies in 2025. Trend: 2023 $417 · 2024 $921 · 2025 $811
Food & beverage: $811
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $298 |
| GENZYME CORPORATION | 9 | $206 |
| CSL Behring | 3 | $72 |
| GlaxoSmithKline, LLC. | 2 | $48 |
| Novartis Pharmaceuticals Corporation | 2 | $43 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $42 |
| Cycle Pharmaceuticals Inc | 1 | $27 |
| Organon LLC | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: FASENRA, DUPIXENT, AYVAKIT, Rhapsido, NEFFY, Andembry, TEZSPIRE, Haegarda.
Industry payments across CA — which companies pay providers there.
